Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
VIVUS
company
About
VIVUS, Inc. is a drug-development company dedicated to the development and commercialization of next-generation therapeutic products
- 51 - 100
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $33.60M
- Industries
- Biopharma,Biotechnology,Health Care
- Founded date
- Jan 1, 1991
- Number Of Employee
- 51 - 100
- Operating Status
- Active
VIVUS, Inc. is a drug-development company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity, diabetes, sleep apnea and sexual health.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$33.60M
VIVUS has raised a total of
$33.60M
in funding over 2 rounds. Their latest funding was raised on
Nov 20, 2020 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 20, 2020 | Post-IPO Equity | $33.60M | 1 |
Caxton Advantage Life Sciences Fund
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
VIVUS is funded by 1 investors.
Caxton Advantage Life Sciences Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Caxton Advantage Life Sciences Fund
|
Yes | Post-IPO Equity |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
